

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

Assignment ID: PATI926749

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST
CONVEYING PARTY DATA	
Name	Execution Date
JPMORGAN CHASE BANK, N.A., as Administrative Agent	03/28/2025
RECEIVING PARTY DATA	
Company Name:	EAGLE BIOLOGICS, INC.
Street Address:	50 Tice Blvd., Suite 315
City:	Woodcliff Lake
State/Country:	NEW JERSEY
Postal Code:	07677
PROPERTY NUMBERS Total: 10	
Property Type	Number
Application Number:	15516074
Application Number:	15903635
Application Number:	15903523
Application Number:	15890044
Application Number:	15809602
Application Number:	17073618
Application Number:	17067058
Application Number:	17101063
Application Number:	18635538
Application Number:	18438199
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	8004945225
Email:	ipteam@cogencyglobal.com
Correspondent Name:	Jay daSilva
Address Line 1:	1025 Connecticut Avenue NW
Address Line 2:	Suite 712
Address Line 4:	Washington, DISTRICT OF COLUMBIA 20036
ATTORNEY DOCKET NUMBER:	2703230 JD PT REL B

PATENT

NAME OF SUBMITTER:	Jay daSilva
SIGNATURE:	/Jay daSilva/
DATE SIGNED:	04/01/2025
Total Attachments: 4 source=B. Eagle Biologics - Patent Release#page1.tiff source=B. Eagle Biologics - Patent Release#page2.tiff source=B. Eagle Biologics - Patent Release#page3.tiff source=B. Eagle Biologics - Patent Release#page4.tiff	

RELEASE OF SECURITY INTEREST IN PATENTS

This RELEASE OF SECURITY INTEREST IN PATENTS (this “Release”), dated as of March 28, 2025, is made by JPMORGAN CHASE BANK, N.A., chartered under the laws of Ohio and having an address of 10 South Dearborn, Chicago, Illinois 60603, in its capacity as administrative agent (the “Administrative Agent”), in favor of EAGLE BIOLOGICS, INC., a Delaware corporation and having an address of 50 Tice Blvd, Suite 315 (“Eagle”).

WHEREAS, reference is made to the following Confirmatory Grants of Security Interest in United States Patents by and among Eagle and the Administrative Agent pursuant to which Eagle granted a security interest to the Administrative Agent in certain patents listed on Schedule I: (i) dated November 8, 2019, recorded at the USPTO on October 24, 2022 at Reel 061513 Frame 0703; (ii) dated November 1, 2022, recorded at the USPTO on November 1, 2022 at Reel 061614 Frame 0716; and (iii) dated October 11, 2024, recorded at the USPTO on October 11, 2024 at Reel 068873 Frame 0905 (the “Notices”; all capitalized terms used, but not otherwise defined herein, shall have the respective meanings ascribed in or otherwise referenced in the Notices); and

WHEREAS, the Administrative Agent, on behalf of itself and each of the other Secured Parties, now agrees to terminate and grant a release of the security interest in and lien upon the patents listed on Schedule I attached hereto owned by Eagle as provided in this Release;

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent, on behalf of itself and the other Secured Parties, hereby agrees as follows:

1. Release of Security Interest. The Administrative Agent, without representation or warranty of any kind, hereby releases, discharges, terminates and cancels all of its security interest in and to and general lien upon, and any conditional collateral assignments of, the patents owned by Eagle listed on Schedule I annexed hereto and made a part hereof, together with all registrations and recordings thereof, all applications in connection therewith, all products and proceeds thereof and any goodwill of the business connected with, and symbolized by, any of the foregoing, and assigns, conveys and transfers to Eagle, without recourse, all of the Administrative Agent’s right, title and interest in such patents and patent applications, and any right, title or interest of the Administrative Agent in such patents and patent applications shall hereby cease and be void.

2. No Other Release. The foregoing release is a release only of the security interest in the patents listed on Schedule I attached hereto and does not constitute a release of the security interest in any other patents.

3. USPTO. The Administrative Agent authorizes the United States Patent and Trademark Office (the “USPTO”) and any other applicable governmental authority to record this Release and understands and agrees that this Release may be recorded by or for Eagle with the USPTO or any similar office or agency within or outside the United States.

**JPMORGAN CHASE BANK, N.A., as Administrative
Agent**

A handwritten signature in dark ink, appearing to read "Daniel Luby", is positioned above a horizontal line.

By: _____

Name: Daniel Luby

Title: Executive Director

Schedule I

UNITED STATES REGISTERED PATENTS

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
20180228831 15516074	16-AUG-2018 31-MAR-2017	POLYSACCHARIDE AND NUCLEIC ACID FORMULATIONS CONTAINING VISCOSITY- LOWERING AGENTS	EAGLE BIOLOGICS, INC.	PUBLISHED
20180177876 15903635	28-JUN-2018 23-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING THIAMINE	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180177875 15903523	28-JUN-2018 23-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING CIMETIDINE	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180153997 15890044	07-JUN-2018 06-FEB-2018	LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED
20180085463 15809602	29-MAR-2018 10-NOV-2017	LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS	EAGLE BIOLOGICS, INC. (APPLICANT)	PUBLISHED

Patent No./ Publication No./ Application No.	Issue Date/ Pub. Date/ App. Date	Title	Current Owner	Status
20210030877 17073618	04-FEB-2021 19-OCT-2020	LIQUID PROTEIN FORMULATIONS CONTAINING IONIC LIQUIDS	EAGLE BIOLOGICS, INC.	PUBLISHED
20210038718 17067058	11-FEB-2021 09-OCT-2020	LIQUID PROTEIN FORMULATIONS CONTAINING ORGANOPHOSPHATES	EAGLE BIOLOGICS, INC.	PUBLISHED
20210085792 17101063	25-MAR-2021 23-NOV-2020	LIQUID PROTEIN FORMULATIONS CONTAINING VISCOSITY- LOWERING AGENTS	EAGLE BIOLOGICS, INC.	PUBLISHED

Title	Country Name	Status	Date Filed	Application #	Grant Date	Patent #	Recorded Owner
Liquid Protein Formulations Containing Ionic Liquids	United States of America	Pending	04/15/2024	18/635,538			Eagle Biologics, Inc.
Liquid Protein Formulations Containing Viscosity-Lowering Agents	United States of America	Published	02/09/2024	18/438,199			Eagle Biologics, Inc.